Drug misuse in pregnancy: Losing sight of the baby?

Archives of Disease in Childhood

Volumn 94, Issue 9, 2009, Pages 708-712

  McGlone, L ^a   Mactier, H ^a   Weaver, L T ^b  

^a UK   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; OPIATE;

DISEASE ASSOCIATION; DRUG MISUSE; EVOKED VISUAL RESPONSE; FETUS; HUMAN; INFANT; INTRAUTERINE GROWTH RETARDATION; NERVE CELL DIFFERENTIATION; NEWBORN; NONHUMAN; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; REVIEW; VISUAL DISORDER; WITHDRAWAL SYNDROME;

ADULT; CHILD DEVELOPMENT; DRUG USERS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; INFANT, NEWBORN; MOTHERS; NEUROGENESIS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; VISION, OCULAR; YOUNG ADULT;

EID: 69249086212     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2008.156851     Document Type: Review

References (66)

1. Johnson K, Gerada C, Greenough A. Substance misuse during pregnancy. Br J Psychiatry 2003;183:187-189
2. Hidden Harm. The report of the enquiry by the Advisory Council on the Misuse of Drugs. London: UK Home Office, 2003.
3. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2)CD002209.
4. Burns L, Mattick RP, Lim K, et al. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007;102:264-270 (Pubitemid 46096288)
5. Arlettaz R, Kashiwagi M, Das-Kundu S, et al. Methadone maintenance program in pregnancy in a Swiss perinatal centre: neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005;84:145-150 (Pubitemid 40278802)
6. Lloyd DJ, Myserscough EJ. Substance misuse research - neonatal abstinence syndrome. A new intervention: A community based, structured health visitor assessment. Scottish Executive Social Research Substance Misuse Research Programme 2006 (web only publication). http://www.scotland.gov.uk/Publications/ 2006/09/04102243/0 (accessed 28 Jan 2009).
7. Lissauer T, Ghaus K, Rivers R. Maternal drug abuse-effects on the child. Curr Paediatr 1994;4:235-239
8. Dashe JS, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gyn 2002;100:1244-1249
9. Berghella V, Lim PJ, Hill MK, et al. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003;189:312-317
10. McCarthy JJ, Leamon MH, Parr MS, et al. High-dose methadone maintenance in pregnancy: Maternal and neonatal outcomes. Am J Obstet Gyn 2005;193:606-610 (Pubitemid 41261451)
11. Dryden C, Young D, Hepburn M, et al. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for health care resources. BJOG. Published Online First: 11 February 2009. doi:10.1111/j.1471-0528.2008.02073.x.
12. Johnson K, Greenough A, Gerada C. Maternal drug use and length of neonatal unit stay. Addiction 2003;98:785-789 (Pubitemid 36688063)
13. Choo RE, Huestis MA, Schroeeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004;75:253-260
14. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-1193 (Pubitemid 35398691)
15. Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatrics 1976;88:1044-1048
16. Philipp B, Merewood A, O'Brien S. Methadone and breastfeeding: new horizons. Pediatrics 2003;111:1429-1430
17. Jackson L, Ting A, McKay S, et al. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2004;89:F300-4. (Pubitemid 38869667)
18. Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews 2005;(1):CD002059.
19. Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2003;88:F2-5.
20. Coyle MG, Ferguson A, LaGasse L, et al. Neurobehavioural effects of treatment for opiate withdrawal. Arch Dis Child Fetal Neonatal Ed 2005;90:F73-4. (Pubitemid 40040212)
21. Bell J, Harvey-Dodds L. Pregnancy and injecting drug use. BMJ 2008;336:1303-1305
22. Hunt RW, Tzioumi D, Collins E, et al. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Human Dev 2008;84:29-35.
23. Rosen TS, Johnson HL. Children of methadone-maintained mothers: follow-up to 18 months of age. J Pediatr 1982;101:192-196
24. Bunikowski R, Grimmer I, Heiser A, et al. Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr 1998;157:724-730 (Pubitemid 28419099)
25. van Baar A, de Graaff BMT. Cognitive development at preschool-age of infants of drug-dependent mothers. Dev Med Child Neurol 1994;36:1063-1075
26. Lifschitz MH, Wilson GS, O'Brian Smith E, et al. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 1985;75:269-274 (Pubitemid 15164788)
27. Wilson GS, Desmond MM, Wait RB. Follow-up of methadone treated and untreated narcotic-dependent women and their infants: health, developmental and social implications. J Pediatr 1981;98:716-722
28. Wilson GS, McCreary R, Kean J, et al. The development of pre-school children of heroin-addicted mothers: a controlled study. Pediatrics 1979;63:135-141 (Pubitemid 9111213)
29. Olofsson M, Buckley W, Andersen GE, et al. Investigation of 89 children born by drug-dependent mothers. Follow-up 1-10 years after birth. Acta Paediatr Scand 1983;72:407-410
30. Ornoy A, Michailevskaya V, Lukashov I, et al. The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted. Child Abuse Neglect 1996;20:385-396 (Pubitemid 26138636)
31. Ornoy A, Segal J, Bar-Hamburger R, et al. Developmental outcome of school-age children born to mothers with heroin-dependency: importance of environmental factors. Dev Med Child Neurol 2001;43:668-675 (Pubitemid 32982227)
32. Topley J, Windsor D, Williams R. Behavioural, developmental and child protection outcomes following exposure to Class A drugs in pregnancy. Child: care, health and dev 2007;34:71-76 (Pubitemid 350302409)
33. Good WV, Ferriero DM, Golabi M, et al. Abnormalities of the visual system in infants exposed to cocaine. Ophthalmology 1992;99:341-346
34. Block SS, Moore BD, Scharre JE. Visual anomalies in young children exposed to cocaine. Optom Vis Sci 1997;74:28-36. (Pubitemid 27114506)
35. Dominguez R, Vila-Coro A, Slopis JM. Brain and ocular abnormalities in infants with in utero exposure to cocaine and other street drugs. Am J Dis Child 1991;146:278-279
36. Stromland K, Pinazo-Duran MD. Ophthalmic involvement in the fetal alcohol syndrome: clinical and animal model studies. Alcohol Alcohol 2002;37:2-8. (Pubitemid 34173301)
37. Chan T, Bowell R, O'Keefe M, et al. Ocular manifestations in fetal alcohol syndrome. Br J Ophthalmol 1991;75:524-526
38. Ribeiro IM, Vale PJ, Tenedorio PA, et al. Ocular manifestations in fetal alcohol syndrome. Eur J Ophthalmol 2007;17:104-109 (Pubitemid 46580605)
39. Stromland K, Pinazo-Duran MD. Optic nerve hypoplasia: comparative effects in children and rats exposed to alcohol in pregnancy. Teratology 1994;50:100-111 (Pubitemid 24289111)
40. Gill AC, Oei J, Lewis NL, et al. Strabismus in infants of opiate-dependent mothers. Acta Paediatrica 2003;92:379-385
41. Gaillard MC, Borruat FX. New finding: transitory horizontal pendular nystagmus secondary to neonatal abstinence syndrome. Klin Monatsbl Augenheilkd 2002;219:317-319
42. Mulvihill AO, Cackett PD, George ND, et al. Nystagmus secondary to drug exposure in utero. Br J Ophthalmol 2007;91:613-615
43. Odom JV, Bach M, Barber C, et al. Visual evoked potential standard. Doc Ophthalmol 2004;108:115-123
44. Taylor MJ, McCulloch DL. Visual evoked potentials in infants and children. J Clin Neurophysiol 1992;9:357-372
45. Benavente I, Tamargo P, Tajada N, et al. Flash visually evoked potentials in the newborn and their maturation during the first six months of life. Doc Ophthalmol 2005;110:255-263 (Pubitemid 41762479)
46. Pike AA, Marlow N, Reber C. Maturation of the flash visual evoked potential in preterm infants. Early Hum Dev 1999;54:215-222 (Pubitemid 29115005)
47. Pieh C, McCulloch DL, Shahani U, et al. Maturation of steady-state flicker VEPs in infants: fundamental and harmonic temporal response frequencies. Doc Ophthalmol 2009;118:109-119
48. Shepherd AJ, Saunders KJ, McCulloch DL. Development of the pattern reversal visual evoked potential in preterm and full term infants. Perception 1997;26:755.
49. Kato T, Watanabe K. Visual evoked potential in the newborn: Does it have predictive value? Semin Fetal Neo Med 2006;11:459-463
50. Taylor MJ, McCulloch DL. Prognostic value of VEPs in young children with acute onset cortical blindness. Pediatr Neurol 1991;7:111-115
51. McCulloch DL, Taylor MJ, Whyte HE. Visual evoked potentials and visual prognosis following perinatal asphyxia. Arch Ophthalmol 1991;109:229-233
52. Shepherd AJ, Saunders KJ, McCulloch DL, et al. Prognostic value of flash visual evoked potentials in preterm infants. Dev Med Child Neurol 1999;41:9-15. (Pubitemid 29027541)
53. Pike AA, Marlow N. The role of cortical evoked responses in predicting neuromotor outcome in very preterm infants. Early Hum Dev 2000;57:123-135 (Pubitemid 30100528)
54. Kato T, Hayakawa F, Okumura A, et al. Flash visual evoked potentials in preterm infants; Correlation with neurodevelopmental outcome. J Jpn Soc Perinat Neonat Med 2000;36:248.
55. Taylor MJ, Murphy WJ, Whyte HE. Prognostic reliability of somatosensory and visual evoked potentials of asphyxiated term infants. Dev Med Child Neurol 1992;34:507-515
56. Whyte HE, Taylor MJ, Menzies R, et al. Prognostic utility of visual evoked potentials in term asphyxiated neonates. Pediatr Neurol 1986;2:220-223 (Pubitemid 17031242)
57. Muttitt SC, Taylor MJ, Kobayashi JS, et al. Serial visual evoked potentials and outcome in term birth asphyxia. Pediatr Neurol 1991;7:86-90.
58. Whyte HE. Visual-evoked potentials in neonates following asphyxia. Clin Perinatol 1993;20:451-461
59. Atkinson J, Braddick O, Anker S, et al. Cortical vision, MRI and developmental outcome in preterm infants. Arch Dis Child Fetal Neonatal Ed 2008;93:F292-7.
60. Mercuri E, Haataja L, Guzzetta A, et al. Visual function in term infants with hypoxic-ischaemic insults: correlation with neurodevelopment at 2 years of age. Arch Dis Child Fetal Neonatal Ed 1999;80:F99-104. (Pubitemid 29122208)
61. Bauer LO. Effects of chronic opioid dependence and HIV-1 infection on pattern shift visual evoked potentials. Drug Alcohol Depend 1998;50:147-155
62. Bauer LO, Easton C. Pattern shift VEPs in abstinent cocaine-dependent, alcoholdependent and cross-dependent patients. Drug Alcohol Depend 1996;40:203-209 (Pubitemid 26131383)
63. Meinck HM, Adler L, Rader K, et al. Delayed visual evoked potentials in chronic alcoholism. J Neurol 1986;233:161-163 (Pubitemid 16114596)
64. Posthuma J, Visser SL, de Rijke W. Peripheral nerve conduction, visual evoked potentials and vitamin B1 serum level in chronic alcoholics. Clin Neurol Neurosurg 1983;85:267-272 (Pubitemid 14201868)
65. Pinto F, Onofrj M, Pola P, et al. Fetal addiction to methadone: postnatal abstinence syndrome and development of visual evoked potentials. Drug Alcohol Depend 1986;18:1-10. (Pubitemid 16027697)
66. McGlone L, Mactier H, Hamilton R, et al. Visual evoked potentials in infants exposed to methadone in utero. Arch Dis Child 2008;93:784-786